Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo

被引:108
作者
Arbiser, JL
Larsson, H
Claesson-Welsh, L
Bai, XH
LaMontagne, K
Weiss, SW
Soker, S
Flynn, E
Brown, LF
机构
[1] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA
[3] Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA USA
[4] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA
[5] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden
关键词
D O I
10.1016/S0002-9440(10)65015-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular endothelial growth factor (VEGF or vascular permeability factor) is an important angiogenic factor that is up-regulated in numerous benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors. To determine the functional role of VEGF in the development of endothelial tumors, we expressed primate VEGF 121 in an endothelial cell line, MS1, derived from primary murine cells by immortalization with a temperature-sensitive SV40 large T antigen. This cell line expresses the VEGFR-2 (Flk-1/Kdr) receptor for VEGF. Expression of VEGF 121 led to the development of slowly growing endothelial tumors, which were histologically well-differentiated angiosarcomas. The angiosarcomas generated from MS1 VEGF cells demonstrated up-regulation of the VEGF receptors VEGFR-2 and VEGFR-1 (Flt-1) in vivo compared with benign hemangiomas generated from MS1 cells. Treatment of these cells with the VEGFR-2 tyrosine kinase inhibitor SU 1498 led to decreased expression of ets-1, a transcription factor which has been shown to be stimulated by VEGF. These results suggest that high level expression of VEGF in endothelial cells may result in malignant transformation. This transformation process likely involves both autocrine and paracrine pathways.
引用
收藏
页码:1469 / 1476
页数:8
相关论文
共 47 条
[1]   Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].
Arbiser, JL ;
Moses, MA ;
Fernandez, CA ;
Ghiso, N ;
Cao, YH ;
Klauber, N ;
Frank, D ;
Brownlee, M ;
Flynn, E ;
Parangi, S ;
Byers, HR ;
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866
[2]  
Barbin A, 1997, CANCER RES, V57, P1695
[3]   Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: Case report and review of the literature [J].
Blei, F ;
Karp, N ;
Rofsky, N ;
Rosen, R ;
Greco, MA .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1998, 15 (04) :295-305
[4]   POSTTREATMENT SARCOMA IN BREAST-CANCER PATIENTS [J].
BRADY, MS ;
GARFEIN, CF ;
PETREK, JA ;
BRENNAN, MF .
ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (01) :66-72
[5]  
Brown LF, 1996, AM J PATHOL, V148, P1065
[6]   VASCULAR-PERMEABILITY FACTOR MESSENGER-RNA AND PROTEIN EXPRESSION IN HUMAN KIDNEY [J].
BROWN, LF ;
BERSE, B ;
TOGNAZZI, K ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR ;
DVORAK, HF ;
ROSEN, S .
KIDNEY INTERNATIONAL, 1992, 42 (06) :1457-1461
[7]   CUTANEOUS ANGIOSARCOMA ARISING IN THE RADIATION SITE OF A CONGENITAL HEMANGIOMA [J].
CALDWELL, JB ;
RYAN, MT ;
BENSON, PM ;
JAMES, WD .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 33 (05) :865-870
[8]  
Claffey KP, 1996, CANCER RES, V56, P172
[9]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[10]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25